| |
In April, BioIVT hosted a symposium on methodologies and techniques for in vitro ADME / drug interaction research featuring speakers from industry, academia, and BioIVT. Learn More and View the Presentations >>
|
|
Today’s Big NewsJun 24, 2024 |
| By Annalee Armstrong After a full data analysis, Altimmune is heralding phase 2 obesity data for pemvidutide as “best-in-class” for spurring weight loss while preserving lean mass. |
|
|
|
By Annalee Armstrong Searching for a path forward after the withdrawal of Relyvrio in amyotrophic lateral sclerosis, Amylyx Pharmaceuticals has purchased a GLP-1 receptor antagonist from Eiger Biopharma for $35.1 million. |
By James Waldron The past couple of years have seen Big Pharmas whip out their wallets to place high-stake bets in the red-hot races for antibody-drug conjugates, radiopharmaceuticals and obesity drugs, to name a few. We wanted to take another look at some of the deals that have kept our attention. |
Sponsored by Cardinal Health CGT companies should consider developing a market access strategy early in clinical development, ideally more than three years prior to launch. |
By James Waldron Takeda may have pruned back the potential indications for mezagitamab, but the latest raft of phase 2 data suggest that the anti-CD38 antibody could still “transform treatment” of primary immune thrombocytopenia (ITP). |
By James Waldron Alumis is eyeing up potential proceeds of over $300 million that the biotech will use to fund its TYK2 inhibitor through phase 3 psoriasis trials. |
By Gabrielle Masson It’s the end of an era—eFFECTOR Therapeutics’ era to be exact. The oncology biotech has laid off staff as it plans to wind down, according to a June 24 release. |
By Nick Paul Taylor Novo Nordisk has shared a closer look at phase 3 results on its hemophilia A candidate Mim8, revealing new data that show how it squares up against Roche’s blockbuster Hemlibra on key measures of efficacy and tolerability. |
By Helen Floersh GLP-1 drugs like Eli Lilly's Zepbound and Novo Nordisk's Wegovy work to address obesity—as long as a patient keeps taking them. Harith Rajagopalan, M.D., Ph.D. thinks his company, Fractyl Health, may have the answer. |
By Fraiser Kansteiner Late last week, Lilly shared detailed results from its phase 3 SURMOUNT-OSA study, which found that Zepbound at the 10 mg and 15 mg doses aced its primary and secondary endpoints in obese patients with obstructive sleep apnea (OSA). |
By Angus Liu In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events. The result appears to be a best-case scenario for Alnylam, but analysts are still eager to see detailed data from Amvuttra's combination with Pfizer's tafamidis. |
By Heather Landi Artificial intelligence can play a key role in diabetes management programs by enabling more personalized health "nudges" for members, which drives higher engagement and better health outcomes, according to new data released by Teladoc Health. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing. |
|
|---|
|
|
| WebinarWatch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| WhitepaperThis detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
